Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Dec 14;32(12):E63–E67. doi: 10.1002/clc.20550

Three Year Follow‐up of the Sirolimus‐Eluting Stent and the Paclitaxel‐eluting Stent in Daily Practice

Zhan Gao 1, Yuejin Yang 1,✉, Bo Xu 1, Jilin Chen 1, Shubin Qiao 1, Jianjun Li 1, Yongjian Wu 1, Xuewen Qin 1, Jinqing Yuan 1, Runlin Gao 1
PMCID: PMC6653084  PMID: 20014187

Abstract

Background

Although the efficacy and safety of Cypher and Taxus stents for particular patients and lesions had been proven by random clinical trials, their long‐term comparative effect for unselected Chinese patients in daily practice is still unknown.

Methods

From April 2004 to April 2005, 682 consecutive patients who were implanted with a Cypher stent (C group: n = 456, 57.3 ± 10.8 years old) or a Taxus stent (T group: n = 226, 57.2 ± 10.2 years old) in our center were analyzed. A mean 3 year clinical and 7 month angiographic follow‐up was performed.

Results

There was no difference in major adverse cardiac events (MACE) rates in the C and T groups (16.4% vs 21.7%; P = .113), and there was also no difference in cardiac death or myocardial infarction (MI) rates in both groups (2.6% vs 1.8%; P = .598, 3.3% vs 3.5%; P = .826 respectively), but target vessel revascularization (TVR) was higher in the T group (10.5% vs 16.4%; P = .036). There was no difference in total stent thrombosis or its components in both groups (total: 3.9% vs 3.5%; P = 1.000, early: 0.2% vs 0.9%; P = .256, late: 0.7% vs 1.3%; P = .404, and very late: 3.1% vs 1.3%; P = .201 respectively). A 7 month angiographic follow‐up indicated that both in‐stent and in‐segment restenosis rate were significantly lower in the C group (11.1% vs 21.0%; P = .034 and 12.2% vs 24.0%; P = .018), and in‐stent and in‐segment late loss were significantly smaller in the C group (0.18 ± 0.08 mm vs 0.53 ± 0.38 mm; P = .000 and 0.17 ± 0.09 mm vs 0.38 ± 0.19 mm; P = .000).

Conclusion

Results from this 3 year follow‐up, single‐center study showed almost the same effective and safe profile for both Cypher and Taxus stents, except for a better reducing restenosis effect in the Cypher stent. Copyright © 2009 Wiley Periodicals, Inc.

Keywords: Percutaneous coronary intervention, Drug eluting stent, long‐term, follow‐up

Full Text

The Full Text of this article is available as a PDF (102.9 KB).

References

  • 1. Williams DO, Abbott JD, Kip KE; DEScover Investigators. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug‐eluting stents: report of the DEScover Registry. Circulation 2006; 114: 2154–2162. [DOI] [PubMed] [Google Scholar]
  • 2. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus‐ and paclitaxel‐eluting coronary stent. N Engl J Med 2007; 356: 998–1008. [DOI] [PubMed] [Google Scholar]
  • 3. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus‐eluting stents with bare‐metal stents. N Engl J Med 2007; 356: 989–997. [DOI] [PubMed] [Google Scholar]
  • 4. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus‐eluting stents with bare‐metal stents. N Engl J Med 2007; 356: 1030–1039. [DOI] [PubMed] [Google Scholar]
  • 5. Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel‐eluting or sirolimus‐eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663–670. [DOI] [PubMed] [Google Scholar]
  • 6. Dawkins KD, Grube E, Guagliumi G, et al. Clinical efficacy of polymer‐based paclitaxel‐eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug‐eluting stents in contemporary clinical practice. Circulation 2005; 112: 3306–3313. [DOI] [PubMed] [Google Scholar]
  • 7. Chieffo A, Morici N, Maisano F, et al. Percutaneous treatment with drug‐eluting stent implantation versus bypass surgery for unprotected left main stenosis: a single‐center experience. Circulation 2006; 113: 2542–2547. [DOI] [PubMed] [Google Scholar]
  • 8. Spaulding C, Henry P, Teiger E, et al. Sirolimus‐eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355: 1093–1104. [DOI] [PubMed] [Google Scholar]
  • 9. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in‐stent restenosis with a paclitaxel‐coated balloon catheter. N Engl J Med 2006; 355: 2113–2124. [DOI] [PubMed] [Google Scholar]
  • 10. Sabate M, Jimenez‐Quevedo P, Angiolillo DJ, et al. Randomized comparison of sirolimus‐eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus‐eluting stent (DIABETES) trial. Circulation 2005; 112: 2175–2183. [DOI] [PubMed] [Google Scholar]
  • 11. Neumann FJ, Desmet W, Grube E, et al. Effectiveness and safety of sirolimus‐eluting stents in the treatment of restenosis after coronary stent placement. Circulation 2005; 111: 2107–2111. [DOI] [PubMed] [Google Scholar]
  • 12. Suttorp MJ, Laarman GJ, Rahel BM, et al. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus‐eluting stent implantation for the treatment of total coronary occlusions. Circulation 2006; 114: 921–928. [DOI] [PubMed] [Google Scholar]
  • 13. Morice MC, Colombo A, Meier B, et al. Sirolimus‐ vs paclitaxel‐eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006; 295: 895–904. [DOI] [PubMed] [Google Scholar]
  • 14. Togni M, Eber S, Widmer J, et al. Impact of vessel size on outcome after implantation of sirolimus‐eluting and paclitaxel‐eluting stents: a subgroup analysis of the SIRTAX trial. J Am Coll Cardiol 2007; 50: 1123–1131. [DOI] [PubMed] [Google Scholar]
  • 15. Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel‐eluting or sirolimus‐eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663–670. [DOI] [PubMed] [Google Scholar]
  • 16. Ong AT, Serruys PW, Aoki J, et al. The unrestricted use of paclitaxel‐ versus sirolimus‐eluting stents for coronary artery disease in an unselected population: one‐year results of the Taxus‐Stent Evaluated at Rotterdam Cardiology Hospital (T‐SEARCH) registry. J Am Coll Cardiol 2005; 45: 1135–1141. [DOI] [PubMed] [Google Scholar]
  • 17. Cutlip DE, Windecker S, Mehran M, et al. Clinical end point in coronary stent trails: a case for standardized definitions. Circulation 2007; 115: 2344–2351. [DOI] [PubMed] [Google Scholar]
  • 18. King SB III, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008; 51: 172–209. [DOI] [PubMed] [Google Scholar]
  • 19. Camenzind E, Steg G, Wijns W. Stent thrombosis late after implantation of first‐generation drug‐eluting stents: a cause for concern. Circulation 2007; 115: 1440–1455. [DOI] [PubMed] [Google Scholar]
  • 20. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug‐eluting vs. bare metal stents in coronary artery disease: a meta‐analysis. Eur Heart J 2006; 27: 2784–2814. [DOI] [PubMed] [Google Scholar]
  • 21. Mauri L, Hsieh W, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug‐eluting stents. N Engl J Med 2007; 356: 1020–1029. [DOI] [PubMed] [Google Scholar]
  • 22. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug‐eluting and bare‐metal stents: a collaborative network meta‐analysis. Lancet 2007; 370: 937–948. [DOI] [PubMed] [Google Scholar]
  • 23. Urban P, Gershlick AH, Guagliumi G, et al. Safety of coronary sirolimus‐eluting stents in daily clinical practice: one‐year follow‐up of the e‐Cypher registry. Circulation 2006; 113: 1434–1441. [DOI] [PubMed] [Google Scholar]
  • 24. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxel‐eluting stents for percutaneous coronary intervention? A meta‐analysis. J Am Coll Cardiol 2005; 45: 941–946. [DOI] [PubMed] [Google Scholar]
  • 25. Moreno R, Fernandez C, Sanchez‐Recalde A, et al. Risk of stent thrombosis after sirolimus or paclitaxel eluting coronary stent implantation. Br J Clin Pharmacol 2007; 64: 110–112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Kastrati A, Dibra A, Eberle S, et al. Sirolimus‐eluting stents vs paclitaxel‐eluting stents in patients with coronary artery disease: meta‐analysis of randomized trials. JAMA 2005; 294: 819–825. [DOI] [PubMed] [Google Scholar]
  • 27. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug‐eluting stents. JAMA 2005; 293: 2126–2130. [DOI] [PubMed] [Google Scholar]
  • 28. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug‐eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519–1521. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES